Skip to content

All Lessons

mRNA Vaccines (Clinical Investigator Training Course 2024)

Mutual Recognition Agreements (MRAs): Overview of MRAs between FDA and Foreign Drug Regulatory Authorities

National Drug Code

Navigating Challenges in Drug Manufacturing: Common Process Deficiencies and Pre-Approval Inspection Observations

Navigating Complexity: Key Considerations in Developing the Oral Semaglutide Product-Specific Guidance

Navigating Formulation Assessment: Considerations for Products that are Not Required to be Q1/Q2

Navigating Formulation Assessment: Considerations When Preparing the Q1/Q2 Sameness Inquiry

Nitrosamine Impacted Drug Products Containing BCS IV Drug Substances

Nitrosamine Related Guidance

Nonclinical Considerations for Cell Therapy Product Development: Discussion Panel

Nonclinical Considerations for Cell Therapy Product Development: Presentations

Office of Generic Drugs Keynote (Generic Drugs Forum 2025)

Office of Pharmaceutical Quality Keynote (Generic Drugs Forum 2025)

Office of Study Integrity and Surveillance (OSIS): Mission and Vision

Opening Remarks and Keynote Address (Interchangeable Products)

Orange Book Marketing Status

Other Considerations Around Interchangeability of Biological Products

Overview of CBER’s Office of Communication, Outreach and Development

Overview of FDA’s Engagement in Trade Policy

Overview of ICH M13 Guideline Series

Panel Discussion (Pre-Sub Meetings)

Panel Discussion (PSG)

Panel Discussion, Panel Discussion and Q&A (M13B Additional Strengths Biowaiver Guideline)

Panel Discussion, Summary, and Close Out (Interchangeable Products)

Patient Engagement (REdI 2024 – Biologics Track)

1 … 8 9 10 11 12 … 16
Share: